Myomo Inc. (MYO) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Myomo Inc. (NYSE: MYO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.30 (+3.18% 1D, market cap $51.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MYO ranks #760 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), MYO carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 65.7%, and ROIC of -35.0%. By comparison, COCH (Envoy Medical Inc. (Class A)) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $50.3M) and APT (Alpha Pro Tech Ltd.) posts a D+ grade (58/100 RQD, P/E 16.2x, ROIC 6.7%, cap $56.6M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).
Per MYO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001369290), Myomo Inc. generated $40.9M in revenue (+25.7% YoY), -$15.6M in net income, and -$16.3M in free cash flow against $38.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 54% of 52W Range • RSI-14 at 42.8 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Capital intensity & 0% operating margin leave 16 pts on the table
While MYO currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.42) and Max Pain ($1.37) forces dealer call-delta covering toward $1.98.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Myomo Inc. (MYO) surged +3.18% to $1.30, trading at 54% of its 52-week range ($0.61 – $1.89). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
OrthoPediatrics, Omada Health, Enovis, Myomo and FIGS span the full arc of physical therapy, from childhood care and prevention to recovery and the professionals who deliver it NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) --
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +25.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MYO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MYO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Myomo Inc. (MYO) ranks #760 by composite RQD confidence (37/100, grade D-) and #747 by equity capitalization ($51.5M). Within this direct 5-issuer industry benchmark cohort, APT leads on earnings valuation at 16.2x trailing P/E, while APT leads on capital efficiency and profitability with 6.7% ROIC and 38.1% gross margin. APT currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with MYO at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MYO
ACTIVE
Myomo Inc. | D- | 37/100 | — | 65.7% | -35.0% | +3.18% | $51.5M | Benchmark Subject |
| COCH Envoy Medical Inc. (Class A) | D- | 42/100 | — | -30.0% | -35.0% | -2.40% | $50.3M | /coch-vs-myo → |
| APT Alpha Pro Tech Ltd. | D+ | 58/100 | 16.2x | 38.1% | 6.7% | +1.28% | $56.6M | /apt-vs-myo → |
| NTRB Nutriband Inc. | D- | 40/100 | — | 27.8% | -35.0% | +3.75% | $80.7M | /ntrb-vs-myo → |
| CNXU Conexeu Sciences Inc. | D+ | 56/100 | — | — | — | -1.74% | $85.8M | /cnxu-vs-myo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Myomo Inc. (MYO) reported GAAP revenue of $40.9M (+25.7% vs. FY2024 revenue of $32.6M , and +112.7% cumulative change since FY2023) , GAAP net income of -$15.6M, operating cash flow of -$14.5M, and free cash flow of -$16.3M (-249.5% YoY). On the balance sheet, MYO closed FY2025 with $38.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $40.9M | -$15.6M | -$14.5M | -$16.3M | $38.6M | — |
| FY2024 (FY) | 2024-12-31 | $32.6M | -$6.2M | -$3.3M | -$4.7M | $42.2M | — |
| FY2023 (FY) | 2023-12-31 | $19.2M | -$8.1M | -$6.2M | -$6.2M | — | — |
As of 2026-11-01, Myomo Inc. (NYSE: MYO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.30 (+3.18% 1D, market cap $51.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MYO ranks #760 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), MYO carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 65.7%, and ROIC of -35.0%. By comparison, COCH (Envoy Medical Inc. (Class A)) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $50.3M) and APT (Alpha Pro Tech Ltd.) posts a D+ grade (58/100 RQD, P/E 16.2x, ROIC 6.7%, cap $56.6M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).
Per MYO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001369290), Myomo Inc. generated $40.9M in revenue (+25.7% YoY), -$15.6M in net income, and -$16.3M in free cash flow against $38.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MYO last traded at $1.30 (+3.18% on volume of 249,472 shares), positioning the stock -8.45% below its 50-day simple moving average ($1.42) and +20.37% above its 200-day simple moving average ($1.08). Across its 52-week range of $0.61 to $1.89, MYO sits at the 53.9% percentile with a 14-day RSI of 42.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.14 to $1.46).
Why MYO Stock surged +3.18% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.